Personalised lifestyle changes found to reverse Alzheimer's. A Drug That Could Slow Parkinson's and Alzheimer's Is Heading to Major Testing. On to the Next Level A drug that has already been approved to treat leukemia is now closer to being approved for use against the debilitating brain diseases, parkinson’s and alzheimer’s.
There are more than 5 million people currently living with Alzheimer’s disease in the US and another million living with parkinson’s. This drug has the potential to change the lives of not just these millions of sufferers, but also their countless friends and family who suffer along with them. Currently, there are no approved drugs to slow or halt the progression of the diseases.
These patients typically take medications and treatments to address the specific symptoms of their disease, which have their own deleterious side-effects. “It was such a small trial, there was no placebo control and it really wasn’t designed to assess efficacy,” says J. Fueling Optimism Years of research studying these neurodegenerative diseases has allowed for new treatments like this to be developed. Alzheimer's treatment within reach after successful drug trial. An Alzheimer’s drug has been shown to successfully target the most visible sign of the disease in the brain, raising hopes that an effective treatment could be finally within reach.
A small trial of the drug was primarily aimed at assessing safety, but the findings suggest it effectively “switched off” the production of toxic amyloid proteins that lead to the sticky plaques seen in the brains of Alzheimer’s patients. If the tablet, produced by pharmaceutical giant Merck, is also shown to slow the pace of mental decline – a crucial question that a major clinical trial should answer when it reports next year – it could be the first treatment for Alzheimer’s to be licensed in more than a decade.
Prof John Hardy, a neuroscientist at UCL who first proposed that amyloid proteins play a central role in Alzheimer’s disease, welcomed the results. “People are excited,” he said. Pollution particles 'get into brain' Image copyright ZEPHYR/SCIENCE PHOTO LIBRARY Tiny particles of pollution have been discovered inside samples of brain tissue, according to new research.
Suspected of toxicity, the particles of iron oxide could conceivably contribute to diseases like Alzheimer's - though evidence for this is lacking. The finding - described as "dreadfully shocking" by the researchers - raises a host of new questions about the health risks of air pollution. Many studies have focused on the impact of dirty air on the lungs and heart. Now this new research provides the first evidence that minute particles of what is called magnetite, which can be derived from pollution, can find their way into the brain. Researchers have devised a treatment called MEND to reverse Alzheimer’s in Early-stage patients. The human toll is evident.
Patients knowing they are going to progressively lose their minds, functionality, and their very lives, must somehow learn to live with the horrifying diagnosis of Alzheimer’s. Meanwhile their families shoulder the burden of care, and the anguish of knowing that someday they will no longer be recognized. Around 5.4 million Americans currently live with this neurodegenerative disorder. This is the sixth most common cause of death in the U.S. By 2050, 13.8 million are projected to have it. What does an 87% accurate Alzheimer's test mean? Not much without positive predictive value.
What does it mean to say that a new test is 87% accurate?
I think most journalists writing about a paper published in the journal Alzheimer’s & Dementia could not satisfactorily answer that question – about a statistic they repeatedly quoted in stories about that paper. The answer is: Not much, if you don’t take positive predictive value into account. And again, most journalists writing about the study won’t know what this means either. Chemical switch found in Alzheimer's and stroke victims' brains kills neurons. Effects of Alzheimer’s.
Image: healthbenefitstimes.com. Alzheimer’s-in-a-dish is ‘first clear evidence’ for amyloid hypothesis. A confocal microscope image of an amyloid-beta deposit (red-orange) in 3D neural cell culture (credit: Se Hoon Choi et al.
/Nature) Massachusetts General Hospital (MGH) researchers have created the first “Alzheimer’s-in-a-dish” — a 3D petri dish capable of reproducing the full course of events underlying the development of Alzheimer’s disease. Alzheimer’s has been thought to result from the buildup of inflammatory plaque formed by the beta-amyloid protein and from another protein, tau, which entangles neurons. Memory Loss From Alzheimer’s Reversed For First Time With New Approach — PsyBlog. Nine out of ten patients with memory problems showed improvements with this novel multi-systems approach.
Memory loss in patients with Alzheimer’s disease may be reversed — and the improvement sustained — using a novel treatment approach, a small exploratory study has found. The study, which included 10 patients, used a combination of therapies which were personalised to help them reverse memory loss (Bredesen, 2014). Some patients were getting disoriented while driving, others mixing up names and some had been forced to quit their jobs. Within three to six months of the treatment all but one of the patients was seeing either objective or subjective improvements in their memory.
Those who had been forced to quit work were able to return. One of the patients was a 55-year-old attorney who had been suffering memory loss for four years, but showed a remarkable improvement from the program: Professor Dale Bredesen, who authored the study, explained that the key is taking a multi-systems approach: New Alzheimer’s treatment fully restores memory function.
Australian researchers have come up with a non-invasive ultrasound technology that clears the brain of neurotoxic amyloid plaques - structures that are responsible for memory loss and a decline in cognitive function in Alzheimer’s patients.
If a person has Alzheimer’s disease, it’s usually the result of a build-up of two types of lesions - amyloid plaques, and neurofibrillary tangles. Amyloid plaques sit between the neurons and end up as dense clusters of beta-amyloid molecules, a sticky type of protein that clumps together and forms plaques. Neurofibrillary tangles are found inside the neurons of the brain, and they’re caused by defective tau proteins that clump up into a thick, insoluble mass. This causes tiny filaments called microtubules to get all twisted, which disrupts the transportation of essential materials such as nutrients and organelles along them, just like when you twist up the vacuum cleaner tube.
You can hear an ABC radio interview with the team here. NTU scientists discover new treatment for dementia. Pushing new frontiers in dementia research, Nanyang Technological University, Singapore (NTU Singapore) scientists have found a new way to treat dementia by sending electrical impulses to specific areas of the brain to enhance the growth of new brain cells.
Known as deep brain stimulation, it is a therapeutic procedure that is already used in some parts of the world to treat various neurological conditions such as tremors or Dystonia, which is characterised by involuntary muscle contractions and spasms. NTU scientists have discovered that deep brain stimulation could also be used to enhance the growth of brain cells which mitigates the harmful effects of dementia-related conditions and improves short and long-term memory. New Alzheimer’s Treatment is Fully Restoring Memory Function. If you’ve ever had anyone in your life suffer from Alzheimer’s disease, you know that it is a brutal condition. Not only for the person suffering from it but for their family and friends.
Alzheimers affects over 50 million people worldwide, and there is no cure or vaccine against it. ALS and Frontotemporal Dementia Linked to Nuclear Transport Problems. NIH-supported studies point to potential new target for treating neurodegenerative diseases. Three teams of scientists supported by the National Institutes of Health showed that a genetic mutation linked to some forms of amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD) may destroy neurons by disrupting the movement of materials in and out of the cell’s nucleus, or command center where most of its DNA is stored. The results, published in the journals Nature and Nature Neuroscience, provide a possible strategy for treating the two diseases. “This research shines a spotlight on the role of nuclear transport in the health of neurons,” said Amelie Gubitz, Ph.D., program director at the NIH’s National Institute of Neurological Disorders and Stroke (NINDS).
“The results provide new insights into how this mutation derails an essential process in neurons and opens new avenues for therapy development.” Both ALS and FTD are caused by the death of specific neurons. New Study Suggests Alzheimer's Is Associated with Brain Fungus. Experimental drug targeting Alzheimer's disease shows anti-aging effects in animal tests. Salk Institute researchers have found that an experimental drug candidate aimed at combating Alzheimer’s disease has a host of unexpected anti-aging effects in animals. The Salk team expanded upon their previous development of a drug candidate, called J147, which takes a different tack by targeting Alzheimer’s major risk factor–old age.
In the new work, the team showed that the drug candidate worked well in a mouse model of aging not typically used in Alzheimer’s research. When these mice were treated with J147, they had better memory and cognition, healthier blood vessels in the brain and other improved physiological features. “Initially, the impetus was to test this drug in a novel animal model that was more similar to 99 percent of Alzheimer's cases,” says Antonio Currais, the lead author and a member of Professor David Schubert’s Cellular Neurobiology Laboratory at Salk. Abstract SOURCES - Salk Institute, Journal Aging. Alzheimer's drug found to cause harm to mouse brain cells. New Understanding of Cause of Alzheimer’s Symptoms. Amyloid plaques may be strangling blood flow. Virginia Tech Carilion Research Institute scientists have uncovered a mechanism in the brain that could account for some of the neural degeneration and memory loss in people with Alzheimer’s disease.
The researchers, together with scientists at the University of Alabama at Birmingham School of Medicine, discovered that a common symptom of Alzheimer’s disease – the accumulation of amyloid plaques along blood vessels – could be disrupting blood flow in the brain. The results were published Monday in the journal Brain. “We’ve always been interested in how glial cells interact with blood vessels,” said Harald Sontheimer, director of the Center for Glial Biology in Health, Disease, and Cancer at the Virginia Tech Carilion Research Institute and senior author of the paper. Slowing Alzheimer’s by Speeding Up Brain’s Waste Disposal.
NIH-funded mouse study identifies therapeutic target for clearing out toxic proteins damaged during neurodegenerative disorders. This New Breakthough Alzheimer’s Treatment Fully Restores Memory Function.